- Home
- STNG vs IBRX Comparison
STNG vs IBRX Comparison
Compare STNG & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STNG
- IBRX
- Stock Information
- Founded
- STNG 2009
- IBRX 2014
- Country
- STNG Monaco
- IBRX United States
- Employees
- STNG N/A
- IBRX N/A
- Industry
- STNG Marine Transportation
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STNG Consumer Discretionary
- IBRX Health Care
- Exchange
- STNG Nasdaq
- IBRX Nasdaq
- Market Cap
- STNG 2.1B
- IBRX 2.4B
- IPO Year
- STNG 2010
- IBRX N/A
- Fundamental
- Price
- STNG $42.40
- IBRX $2.72
- Analyst Decision
- STNG Buy
- IBRX Strong Buy
- Analyst Count
- STNG 4
- IBRX 5
- Target Price
- STNG $60.50
- IBRX $11.40
- AVG Volume (30 Days)
- STNG 1.3M
- IBRX 9.5M
- Earning Date
- STNG 07-29-2025
- IBRX 08-11-2025
- Dividend Yield
- STNG 3.77%
- IBRX N/A
- EPS Growth
- STNG N/A
- IBRX N/A
- EPS
- STNG 10.31
- IBRX N/A
- Revenue
- STNG $1,066,599,000.00
- IBRX $31,222,000.00
- Revenue This Year
- STNG N/A
- IBRX $567.98
- Revenue Next Year
- STNG $1.73
- IBRX $160.56
- P/E Ratio
- STNG $4.12
- IBRX N/A
- Revenue Growth
- STNG N/A
- IBRX 10238.41
- 52 Week Low
- STNG $30.63
- IBRX $1.83
- 52 Week High
- STNG $82.04
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- STNG 56.24
- IBRX 47.24
- Support Level
- STNG $38.83
- IBRX $2.50
- Resistance Level
- STNG $41.44
- IBRX $2.77
- Average True Range (ATR)
- STNG 1.58
- IBRX 0.17
- MACD
- STNG -0.10
- IBRX -0.04
- Stochastic Oscillator
- STNG 58.67
- IBRX 29.73
About STNG Scorpio Tankers Inc.
Scorpio Tankers Inc is a provider of marine transportation of petroleum products. It owned, lease financed, or chartered in vessels spanning three different vessel segments Handymax, MR, and LR2. The company's fleet of tankers is the eco-friendly, and newest fleet on the water hauling clean petroleum products. It provides seaborne transportation of crude oil and refined petroleum products. The company generates the majority of its revenue from LR2.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.